-
Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis.
Experimental dermatology 20120901
-
[A 10-week safety and efficacy evaluation of olopatadine, 0.2% instilled twice-daily in patients with allergic conjunctivitis in Japan].
Nippon Ganka Gakkai zasshi 20120901
-
The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice.
Allergy 20120801
-
Stereoselective syntheses of the antihistaminic drug olopatadine and its E-isomer.
The Journal of organic chemistry 20120720
-
Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
Clinical therapeutics 20120601
-
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.
Archives of dermatological research 20120501
-
The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats.
Biological & pharmaceutical bulletin 20120101
-
Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis.
Expert opinion on drug metabolism & toxicology 20111201
-
Thermal angiooedema induced by hot water.
Acta dermato-venereologica 20110501
-
Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis.
American journal of ophthalmology 20110401
-
A rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of olopatadine concentration in human plasma.
Journal of analytical toxicology 20110301
-
Intrastromal corneal ring segments for bilateral keratoconus in an 11-year-old boy.
Journal of cataract and refractive surgery 20110101
-
Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis.
Drug design, development and therapy 20110101
-
Olopatadine hydrochloride inhibits capsaicin-induced flare response in humans.
Pharmacology 20110101
-
Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.
Allergy and asthma proceedings 20110101
-
Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis.
Allergy and asthma proceedings 20110101
-
Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis.
American journal of rhinology & allergy 20110101
-
Olopatadine suppresses the late phase reaction in parthenium dermatitis.
Indian journal of dermatology, venereology and leprology 20110101
-
Stability-indicating high-performance column liquid chromatography and high-performance thin-layer chromatography methods for the determination of olopatadine hydrochloride in tablet dosage form.
Journal of AOAC International 20110101
-
Dermatitis induced by estrogen and progesterone: dual positive results on the intradermal skin test.
Dermatitis : contact, atopic, occupational, drug 20110101
-
Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis.
Current medical research and opinion 20100701
-
Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.
Eye & contact lens 20100701
-
Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older.
Expert opinion on pharmacotherapy 20100601
-
Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Expert opinion on pharmacotherapy 20100401
-
Olopatadine nasal spray for the treatment of allergic rhinitis.
Expert review of clinical immunology 20100301
-
Histamine stimulates interleukin-6 production through histamine H1 receptors in human amnion cells.
Gynecologic and obstetric investigation 20100101
-
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis.
Allergy and asthma proceedings 20100101
-
Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study.
European journal of ophthalmology 20100101
-
[Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro].
[Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20100101
-
Comprehensive review of olopatadine: the molecule and its clinical entities.
Allergy and asthma proceedings 20100101
-
Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice.
International archives of allergy and immunology 20100101
-
Synergetic effects of prednisolone and olopatadine on atopic dermatitis model of hairless mice.
Pharmacology 20100101
-
Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study.
Allergy and asthma proceedings 20100101
-
Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells.
The Journal of dermatology 20091201
-
Olopatadine hydrochloride inhibits scratching behavior induced by a proteinase-activated receptor 2 agonist in mice.
Journal of dermatological science 20091101
-
Azelastine and olopatadine in the treatment of allergic rhinitis.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20091101
-
Multiple action agents and the eye: do they really stabilize mast cells?
Current opinion in allergy and clinical immunology 20091001
-
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Acta ophthalmologica 20090801
-
Cerebral histamine H1 receptor binding potential measured with PET under a test dose of olopatadine, an antihistamine, is reduced after repeated administration of olopatadine.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20090601
-
Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride.
The Journal of dermatology 20090401
-
Drug approvals: '08 in review. Olopatadine hydrochloride (Patanase) nasal spray.
The Nurse practitioner 20090201
-
Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis.
Journal of dermatological science 20090101
-
Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
Clinical therapeutics 20090101
-
Is conjunctival allergen challenge a model of seasonal rhinoconjunctivitis?
Allergy and asthma proceedings 20090101
-
Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study.
Clinical drug investigation 20090101
-
Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis.
Allergy and asthma proceedings 20090101
-
Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.
BMC ophthalmology 20090101
-
Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit.
Journal of investigational allergology & clinical immunology 20090101
-
Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.
Pharmacology 20090101
-
Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis.
Allergy and asthma proceedings 20090101
-
[Effectiveness of olopatadine therapy in seasonal allergic conjunctivitis].
Oftalmologia (Bucharest, Romania : 1990) 20090101
-
[Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis].
Revista medica del Instituto Mexicano del Seguro Social 20090101
-
Comparison of the conjunctival toxicity of topical ocular antiallergic agents.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20081201
-
Repeated pre-treatment with antihistamines suppresses [corrected] transcriptional up-regulations of histamine H(1) receptor and interleukin-4 genes in toluene-2,4-diisocyanate-sensitized rats.
Journal of pharmacological sciences 20081201
-
Effects of olopatadine in limited scleroderma with peripheral eosinophils.
Geriatrics & gerontology international 20080901
-
Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis.
Archives of dermatological research 20080701
-
The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20080701
-
Effect of olopatadine hydrochloride, an anti-histamine drug, on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.
International immunopharmacology 20080601
-
Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
Experimental eye research 20080501
-
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.
Expert opinion on drug metabolism & toxicology 20080401
-
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Methods and findings in experimental and clinical pharmacology 20080401
-
Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
Current medical research and opinion 20080201
-
Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function.
Pharmacology 20080101
-
The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism.
Pharmacology 20080101
-
P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist.
Drug metabolism and pharmacokinetics 20080101
-
Enhancement of basophil apoptosis by olopatadine and theophylline.
Allergy and asthma proceedings 20080101
-
A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
Allergy and asthma proceedings 20080101
-
Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%.
Allergy and asthma proceedings 20080101
-
Use of olopatadine ophthalmic solution and reactivity of histamine skin testing.
Allergy and asthma proceedings 20080101
-
An assessment of the onset and duration of action of olopatadine nasal spray.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20071201
-
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Current eye research 20071201
-
Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20071101
-
[Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution (Patanol 0.1% ophthalmic solution)].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070901
-
Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801
-
Safety and tolerability of olopatadine 0.2% in children and adolescents.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801
-
The effect of H1 antagonists carebastine and olopatadine on histamine induced expression of CC chemokines in cultured human nasal epithelial cells.
Allergology international : official journal of the Japanese Society of Allergology 20070601
-
Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Current medical research and opinion 20070601
-
Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice.
The British journal of dermatology 20070501
-
Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070201
-
Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines.
Journal of investigational allergology & clinical immunology 20070101
-
Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
Allergy and asthma proceedings 20070101
-
Chronic red eyes. Diagnosis: allergic conjunctivitis due to airborne allergen.
Comprehensive ophthalmology update 20070101
-
Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate.
Allergy and asthma proceedings 20070101
-
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis.
Advances in therapy 20070101
-
Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis.
Allergy and asthma proceedings 20070101
-
Olopatadine attenuates the enhancement of capsaicin-evoked substance P release by bradykinin from cultured dorsal root ganglion neurons.
European journal of pharmacology 20061215
-
Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
Eye & contact lens 20061201
-
Neuronal conditions of spinal cord in dermatitis are improved by olopatadine.
European journal of pharmacology 20061010
-
[Clinical effects of olopatadine hydrochloride on pruritus in skin diseases].
Arerugi = [Allergy] 20061001
-
Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study.
Clinical therapeutics 20061001
-
[The use of 'Antigrippin-maximum' in the complex therapy of patients with acute respiratory diseases].
Voenno-meditsinskii zhurnal 20061001
-
[First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].
Orvosi hetilap 20060910
-
Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK.
Current medical research and opinion 20060901
-
Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment.
Investigative ophthalmology & visual science 20060801
-
[Misleading advertisement on Opatanol].
Nederlands tijdschrift voor geneeskunde 20060701
-
Pharmacotherapy of allergic eye disease.
Expert opinion on pharmacotherapy 20060601
-
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
-
Red, itchy eyes, giant papillae.
Advance for nurse practitioners 20060301
-
Role of substance P in allergic nasal symptoms in rats.
European journal of pharmacology 20060217
-
Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.
Acta ophthalmologica Scandinavica 20060201
-
Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen.
British journal of clinical pharmacology 20060101
-
Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.
Mediators of inflammation 20060101
-
Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo.
Allergy and asthma proceedings 20060101
-
[Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].
Arquivos brasileiros de oftalmologia 20060101
-
Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice.
Pharmacology 20051201
-
Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051201
-
The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice.
European journal of pharmacology 20051107
-
Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051101
-
Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20051001
-
Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051001
-
The various effects of four H1-antagonists on serum substance P levels in patients with atopic dermatitis.
The Journal of dermatology 20051001
-
Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Current medical research and opinion 20050901
-
Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Clinical therapeutics 20050901
-
Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
Current medical research and opinion 20050501
-
A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Clinical therapeutics 20050501
-
Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
Ocular immunology and inflammation 20050201
-
[Examination of effectiveness of olopatadine hydrochloride in atopic dermatitis].
Arerugi = [Allergy] 20050201
-
Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20050101
-
Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis.
The Journal of dermatology 20050101
-
Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis.
Journal of dermatological science 20041201
-
Effects of olopatadine hydrochloride, an antihistamine drug, on skin inflammation induced by repeated topical application of oxazolone in mice.
The British journal of dermatology 20041201
-
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Current medical research and opinion 20041201
-
A review of olopatadine for the treatment of ocular allergy.
Expert opinion on pharmacotherapy 20040901
-
Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance.
Clinical and experimental dermatology 20040901
-
Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.
Current medical research and opinion 20040801
-
Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
Current medical research and opinion 20040801
-
Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study.
Clinical therapeutics 20040801
-
Ocular allergy treatment comparisons: azelastine and olopatadine.
Current allergy and asthma reports 20040701
-
A review of the use of olopatadine in allergic conjunctivitis.
International ophthalmology 20040501
-
Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells.
Biochemical pharmacology 20040401
-
[Olopatadine].
Revue de l'infirmiere 20040401
-
The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20040101
-
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Allergy and asthma proceedings 20040101
-
Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
Arzneimittel-Forschung 20040101
-
Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers.
Human psychopharmacology 20031201
-
Interactions of olopatadine and selected antihistamines with model and natural membranes.
Ocular immunology and inflammation 20031201
-
Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Clinical therapeutics 20031001
-
Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
Acta ophthalmologica Scandinavica 20030801
-
Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Clinical therapeutics 20030801
-
[Opatanol].
Ugeskrift for laeger 20030721
-
One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears.
Clinical therapeutics 20030701
-
Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells.
Cellular immunology 20030701
-
Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Eye & contact lens 20030401
-
[In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].
Journal francais d'ophtalmologie 20030401
-
Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists.
International archives of allergy and immunology 20030301
-
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
Clinical therapeutics 20030301
-
Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort.
Advances in therapy 20030101
-
Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities.
Drug metabolism and disposition: the biological fate of chemicals 20021201
-
A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
Clinical therapeutics 20021001
-
Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model.
Clinical therapeutics 20020901
-
Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study.
Clinical therapeutics 20020801
-
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
Clinical therapeutics 20020701
-
Occupational allergy caused by Peruvian lily (Alstroemeria).
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020601
-
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Clinical therapeutics 20020601
-
Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020501
-
Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.
Biochemical and biophysical research communications 20020412
-
Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
Japanese journal of pharmacology 20020401
-
Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils.
Japanese journal of pharmacology 20020401
-
Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
Allergy and asthma proceedings 20020101
-
Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20011101
-
Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and the scratching behavior induced by poly-L-arginine in rats.
Japanese journal of pharmacology 20011001
-
Mucus fishing syndrome: case report and new treatment option.
Optometry (St. Louis, Mo.) 20011001
-
Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Clinical therapeutics 20010801
-
[Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010701
-
Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20010601
-
[Effect of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval in dogs].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010601
-
Inhibitory effect of olopatadine hydrochloride on the sneezing response induced by intranasal capsaicin challenge in guinea pigs.
Japanese journal of pharmacology 20010601
-
Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs.
Japanese journal of pharmacology 20010401
-
Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 19971201
-
The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 19960101